DR. STUART M. ESSIG

Regenerative medicine continues to transform healthcare by helping clinicians repair, restore, and replace damaged tissues with advanced technologies. At the forefront of this evolution is Integra LifeSciences, a global medical technology company headquartered in Princeton, New Jersey, with a strong international presence, including operations in Andorra and other global markets. Since its founding in 1989, the company has focused on one mission—restoring lives through innovative solutions in neurosurgery, tissue reconstruction, and regenerative care. 

Integra LifeSciences has built its reputation by combining decades of scientific research with practical clinical expertise. The company develops products that support surgeons in some of the most complex procedures involving the brain, spine, soft tissue, and advanced wound management. Its regenerative technologies are trusted by healthcare professionals worldwide because they are backed by extensive clinical evidence and designed to improve patient outcomes. 

A major strength of Integra LifeSciences lies in its leadership in regenerative medicine. The company’s tissue regeneration platform has evolved into a broad portfolio of products that help repair skin, nerves, soft tissue, and dura mater. These technologies have played an important role in treating burn injuries, chronic wounds, reconstructive procedures, and neurological conditions. Over the years, strategic acquisitions have expanded Integra’s capabilities, adding advanced wound care, neurosurgical technologies, ENT solutions, and specialty surgical instruments that complement its regenerative medicine expertise. The company’s acquisition of the Codman Neurosurgery business strengthened its position as a global leader in neurosurgical products, while more recent additions have expanded its capabilities in tissue reconstruction and ear, nose, and throat surgery. 

The company’s healthcare portfolio reflects this broad expertise. Its neurosurgery solutions include tissue ablation, dural repair, cranial reconstruction, electrosurgery, minimally invasive surgical technologies, and cranial stabilization systems. In neuro intensive care, Integra provides external cerebrospinal fluid drainage systems, multimodal monitoring technologies, and cranial access solutions. Its hydrocephalus portfolio includes fixed-pressure valves, programmable valves, flow-regulating valves, antimicrobial catheters, and related accessories. Beyond neurology, the company also supports wound reconstruction, soft tissue repair, surgical instruments, and ENT procedures, allowing clinicians to address complex medical challenges across multiple specialties. 

Integra’s purpose extends beyond product development. Guided by its purpose of restoring lives, the company aims to advance transformational care through impactful innovation while enriching life’s important moments. Its values emphasize innovation, collaboration, accountability, quality, and people development. These principles influence everything from research and manufacturing to customer relationships and regulatory compliance. Maintaining high standards of quality and compliance remains central to its operations, ensuring healthcare providers receive safe, reliable, and clinically effective medical technologies. 

Leading this vision is Stuart M. Essig, Ph.D., who returned as President and Chief Executive Officer in May 2026 while continuing to serve as Chairman of the Board. Essig first joined Integra LifeSciences in 1997 and previously led the company as CEO through 2012. During nearly three decades with the organization, he helped grow annual revenues from approximately $15 million to more than $1.6 billion, transforming Integra into one of the world’s leading medical technology companies specializing in neurosurgery and regenerative reconstructive surgery. His experience spans investment banking, corporate governance, healthcare strategy, and medical technology innovation, providing the company with strong leadership during its next phase of growth. 

Innovation at Integra LifeSciences is matched by a commitment to responsible business practices. The company integrates environmental, social, and governance (ESG) principles into its operations while maintaining transparent reporting and continuous improvement across sustainability, ethics, and compliance. Its focus on responsible manufacturing, employee development, product quality, and patient safety reflects a long-term commitment to creating value for healthcare systems, customers, communities, and shareholders alike. 

Today, Integra LifeSciences continues to strengthen its position in regenerative medicine by expanding its portfolio, improving operational excellence, and investing in technologies that address complex surgical needs. Through continuous innovation, evidence-based solutions, and a patient-centered approach, the company remains dedicated to helping surgeons deliver better outcomes while advancing the future of regenerative healthcare. As medicine increasingly shifts toward restoring function rather than simply treating disease, Integra LifeSciences continues to demonstrate why it remains one of the industry’s most trusted names in regenerative medicine.